Mohammad AskarPublic working copy · medical review pending

Ocular surface and surgical risk · 130

Glaucoma drops: protect the ocular surface

Ask about symptoms and daily drop burden, examine the surface and adjust pressure treatment and surface care together.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Preservatives can contribute to surface disease, but active drugs, lids, allergy and the individual eye also matter. Preserve pressure control while reducing avoidable exposure.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Recognise exposure and symptoms

Benzalkonium chloride (BAK) is a commonly used quaternary ammonium preservative with antimicrobial activity. Its effects depend on concentration, number of doses, duration and individual susceptibility; laboratory toxicity is not a direct estimate of injury in each treated eye. 1 2

Chronic preserved-drop exposure may affect the tear film, corneal epithelium, nerves and conjunctiva. Burning, foreign-body sensation, itching, tearing and fluctuating vision can undermine adherence; ask about missed doses without assuming that all symptoms are caused by BAK. 1 2

02Examine the surface and its alternatives

At follow-up, review all bottles, dosing and instillation technique, then examine lids, meibomian glands, tear-film break-up time (TBUT) and fluorescein staining. Selected matrix metalloproteinase-9 (MMP-9) testing can add information, but a positive result is not specific for BAK exposure or proof of surgical scarring. 1 3

Differentiate dry eye, blepharitis, allergy, ocular rosacea and intraocular inflammation. Redness may also be vascular drug-induced hyperaemia; if pressure rises, check technique, adherence, steroid exposure and progressive outflow disease rather than attributing it to surface symptoms alone. 1 3

03Interpret specialised tests and surgical risk

Confocal microscopy can show reduced corneal nerve density in selected patients. Interpret this alongside sensitivity, symptoms and epithelial findings; a nerve image does not identify one toxic mechanism or establish the clinical severity by itself. 1 2

Before filtering surgery, inspect conjunctival inflammation and prior treatment. Chronic multidrug exposure is associated with conjunctival changes, but drug, preservative, duration and disease severity are confounded; a quiet appearance does not exclude subclinical activation and does not guarantee surgical success. 1 2

04Reduce avoidable drop burden

Consider preservative-free formulations or suitable fixed combinations and simplify dosing when pressure targets, access and contraindications permit. Switching can help tolerability in selected patients, but it is not a guarantee of symptom relief or equivalent long-term outcomes for every formulation. 1 2

Add preservative-free lubricants, lid care and treatment of the diagnosed surface disorder. Reassess symptoms, staining and pressure after the change; active ingredients or excipients can remain irritating even without a preservative. 1 2 3

05Select anti-inflammatory treatment and alternatives

The original cyclosporine A 0.05% example concerns selected inflammatory surface disease, not a universal glaucoma adjunct. Product, formulation, local indication, response and tolerability need checking; do not confuse it with other strengths or assume every preparation has the same authorised indication. 1 4

Selective laser trabeculoplasty (SLT) or an appropriate operation may reduce long-term drop dependence in selected eyes. Choose them according to glaucoma type, stage, target pressure and risks; stabilise the surface when possible without delaying urgent pressure treatment. 1 2

06Reassess function, pressure and warning signs

Judge success through pressure, nerve and field stability as well as daily comfort and ability to use treatment. Surface optimisation supports care but does not replace glaucoma surveillance or prove that later filtration failure has been prevented. 1 2

For increasing pain, substantial redness, an epithelial defect or worsening vision, look for corneal infection, inflammation and dangerous pressure as appropriate. Long exposure before filtering surgery merits a documented conjunctival assessment and individual perioperative plan. 1 2

What are the main learning points?

Preservatives can contribute to surface disease, but active drugs, lids, allergy and the individual eye also matter. Preserve pressure control while reducing avoidable exposure.

When is assessment urgent?

Increasing pain, marked redness, an epithelial defect or rapid visual deterioration needs prompt examination; sudden visual loss or suspected infection or neurological disease requires urgent assessment.

References and access status

  1. 1
    Immutable original export; complete own surface/surgical-risk lecture

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    Preserved versus preservative-free glaucoma drops — Hedengran et al., 2020

    Historical access in review 112: complete indexed abstract; editorially reused, no fresh full-paper retrieval. Short-term trials and bias limit long-term safety inference.

  3. 3
    TFOS DEWS II Diagnostic Methodology, 2017

    Historical selected diagnostic text in review 112; not a new appraisal of current TFOS DEWS III or full report.

  4. 4
    EMA Ikervis — product-specific ciclosporin information

    Historical selected indication/dosing and overview in review 112. Does not verify the original0.05% formulation, its local label or every contraindication.